The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSareum Regulatory News (SAR)

Share Price Information for Sareum (SAR)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 26.25
Bid: 26.00
Ask: 26.50
Change: 0.00 (0.00%)
Spread: 0.50 (1.923%)
Open: 26.00
High: 27.75
Low: 26.00
Prev. Close: 26.25
SAR Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Second Price Monitoring Extn

24 Jun 2021 14:05

RNS Number : 0424D
Sareum Holdings PLC
24 June 2021
 

Second Price Monitoring Extension

*Please note that due to low readership, RNS is considering the possible decommissioning of Price Monitoring Extension announcements. We would welcome any feedback you may have about these announcements; in particular, whether you find them valuable and would like to continue receiving them via RNS. Please send feedback to rns@lseg.com *.

A second and final Price Monitoring Extension has been activated in this security. The auction call period is extended in this security for a further 5 minutes.

Following the first price monitoring extension this security would still have executed more than a pre-determined percentage above or below the price of the most recent automated execution today. London Stock Exchange electronic order book users have a final opportunity to review the prices and sizes of orders entered in this security prior to the auction execution.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
APMGZGZVFDKGMZM
Date   Source Headline
3rd Jun 20197:00 amRNSPositive SRA737 data presented at ASCO
16th May 20197:00 amRNSASCO abstracts for SRA737 published
8th May 201912:41 pmRNSSareum notes Sierra Oncology Q1 2019 Results
30th Apr 20197:00 amRNSSareum to Present at BioTrinity 2019 in London
23rd Apr 20197:00 amRNSSRA737 Phase I/IIa data to be presented at ASCO
2nd Apr 20197:00 amRNSPreclinical Data for SRA737 Presented at AACR 2019
12th Mar 20197:00 amRNSSareum Holdings PLC Issue of Options
4th Mar 20197:00 amRNSHALF-YEARLY RESULTS ENDED 31 DECEMBER 2018
28th Feb 20192:04 pmRNSSierra Oncology has reported its 2018 Results
28th Feb 20198:14 amRNSNew SRA737 preclin data to be presented at AACR
23rd Jan 20191:38 pmRNSSierra Oncology to present SRA737 at DDR Tx Summit
18th Dec 201812:35 pmRNSResults of AGM
18th Dec 20187:00 amRNSAGM Statement
30th Nov 201811:17 amRNSAmendment to Preclinical Efficacy Announcement
30th Nov 20187:45 amRNSPreclinical Efficacy for Immunotherapy Combination
15th Nov 201810:24 amRNSPreclinical Data for SRA737 in Ovarian Cancer
14th Nov 20187:00 amRNSAGM NOTICE
13th Nov 20187:00 amRNSDirectorate Change
8th Nov 201812:28 pmRNSSierra Oncology Q3 2018 Results
26th Oct 20187:00 amRNSCompletion of Placing
1st Oct 20187:00 amRNSFINAL RESULTS FOR THE YEAR ENDED 30 JUNE 2018
27th Sep 20181:03 pmRNSNotice of Results
26th Sep 20187:00 amRNSTYK2/JAK1 selected for certain cancers
11th Sep 20187:00 amRNSPre-Close Trading Statement
10th Sep 20187:00 amRNSSelection of TYK2/JAK1 for autoimmune diseases
9th Aug 20181:15 pmRNSSareum notes Sierra Oncology Q2 2018 Results
11th Jul 20189:38 amRNSNotification of PCA Shareholding
15th Jun 20187:00 amRNSAdvisers
31st May 20187:00 amRNSSareum regains rights to Aurora+FLT3 inhibitors
10th May 201812:21 pmRNSSRA737 trial update in Sierra Oncology Q1 Results
24th Apr 20187:00 amRNSSareum to Present at BioTrinity 2018 in London
17th Apr 201812:45 pmRNSAACR 2018 Update
15th Mar 20187:00 amRNSLate-breaker abstract for SRA737 accepted for AACR
13th Mar 20187:00 amRNSInterim Results
27th Feb 201812:50 pmRNSSierra Oncology expands SRA737 development program
22nd Feb 20187:00 amRNSPreclinical synergy of sra737 and PARP inhibitor
13th Feb 20187:00 amRNSNotice of Interim Results
20th Dec 201711:00 amRNSIssue of Options
19th Dec 20177:00 amRNSPatent Grants in Japan & China for TYK2 Inhibitors
14th Dec 201711:01 amRNSResult of AGM
14th Dec 20177:00 amRNSAGM Statement
20th Nov 20177:00 amRNSNotice of AGM and Annual Report & Accounts
14th Nov 201712:05 pmRNSPlacing
31st Oct 20177:00 amRNSSierra Reports Preclinical Data for Chk1 Inhibitor
19th Oct 20177:00 amRNSFinal Results
9th Oct 201712:00 pmRNSSierra Oncology host KOL Meeting on 12 Oct in NY
18th Sep 201712:00 pmRNSSierra Oncology to host call on Chk1 inhibitor
22nd Aug 20177:00 amRNSPre-Close Trading Statement
19th Jun 20177:00 amRNSSareum to Present at the ICCS 2017
5th Jun 201712:13 pmRNSChk1 Clinical Trials Update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.